Hollister Biosciences Inc. Announces Launch of Pre-Roll Production and Distribution in Arizona Psychedelics Investing
Awakn Life Sciences Files Patent Applications in U.S. for AWKN001 and AWKN002, Two Next-Generation New Chemical Entities [NCES] to Treat a Broad Range of Addiction Indications Psychedelics Investing
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression Psychedelics Investing
Seelos Therapeutics Added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes Psychedelics Investing
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species Cannabis Investing News
REPEAT - Silo Wellness Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley Family Psychedelics Investing
Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer Psychedelics Investing
Silo Wellness Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley Family Psychedelics Investing
Psychedelics Biotech Company, Awakn Life Sciences, Goes Public on the NEO Exchange Psychedelics Investing
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association's inaugural Scholars programme Psychedelics Investing
